ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension
April 09, 2024 at 06:50 am EDT
Share
ANI Pharmaceuticals, Inc. announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy. U.S. annual sales for Baclofen Oral Suspension total approximately $39 million, according to IQVIA data.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.